California introduced animal cannabis product standards effective January 1, 2026. The change deserves careful explanation because a product category’s regulatory rules do not establish an appropriate treatment for an individual animal.
What California adopted
DCC states that its standards apply adult-use requirements to animal cannabis products, limit the permitted formats to specified edible, orally consumed concentrate, and topical products, and set a maximum of 1 milligram of total THC per package. The agency lists approval on November 24, 2025 and an effective date of January 1, 2026. Source: DCC animal cannabis product standards.
That package limit is a regulatory ceiling. It is not a dosing recommendation, a declaration that THC is harmless to pets, or guidance for administering a product to an animal.
Federal veterinary evidence is a separate question
FDA says it has not approved cannabis for any use in animals and cannot assure the safety or effectiveness of such products. It recommends discussing treatment options with a veterinarian. Source: FDA cannabis questions, “Pets and other Animals”.
The two agencies’ statements concern different responsibilities. Reporting the California standards without the veterinary context could leave a reader with a stronger impression of demonstrated benefit than the evidence supports.
Keep treatment decisions with veterinary care
A pet’s symptoms should not be treated by converting a human cannabis routine into an animal routine. If an animal may be experiencing adverse effects after cannabis exposure, FDA advises contacting a veterinarian, animal emergency hospital, or animal poison control center immediately.
An accurate account of this legal change should name the state, date, and product restrictions while making clear that a state standard is not a substitute for veterinary assessment.